NCT03482791 is a NA clinical trial of Proton beam therapy in Esophagus Cancer, sponsored by Washington University School of Medicine.

Who is sponsoring NCT03482791?

NCT03482791 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT03482791?

Interventions in NCT03482791: Proton beam therapy, Patient-Reported Outcome Measures.

What condition does NCT03482791 study?

NCT03482791 studies Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus.

Is NCT03482791 still recruiting?

NCT03482791 is currently active, enrolled. Last updated 2 April 2026.

Are results published for NCT03482791?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-04-02 · How we verify

NCT03482791

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proton Beam Therapy in the Treatment of Esophageal Cancer

Active, enrolled NA Results posted Last updated 2 April 2026

What this trial tests

NA trial testing Proton beam therapy in Esophagus Cancer in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 April 2018

Primary endpoint
13 September 2022

9 August 2026

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	19 April 2018
Primary completion	13 September 2022
Estimated completion	9 August 2026
Sites	1 location across United States

Drugs / interventions tested

Proton beam therapy
Patient-Reported Outcome Measures

Conditions studied

Esophagus Cancer — all drugs for Esophagus Cancer →
Esophageal Cancer — all drugs for Esophageal Cancer →
Cancer of the Esophagus — all drugs for Cancer of the Esophagus →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Esophagus Cancer or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the MD Anderson Symptom Inventory (MDASI)-Plus Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The MDASI-Plus is a reliable, validated tool for assessing cancer-related symptoms regardless of therapy or specific cancer diagnosis. Patients are asked to fill out a twenty-seven question inventory. 21 questions ask the patient about the severity of their symptoms with answers ranging from 0=not present to 10=as bad as you can imagine. 6 questions ask the patient about how their symptoms interfered with their life with answers ranging from 0=did not interfere to 10=interfered completely. The higher the score the more severe symptom experience the patient experienced.

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1.994	± 1.641
Arm 2: Unresectable (Proton Beam Therapy)	1.127	± 0.634

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	4.135	± 1.795
Arm 2: Unresectable (Proton Beam Therapy)	3.024	± 2.454

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1.012	± 1
Arm 2: Unresectable (Proton Beam Therapy)	1.31	± 1.112

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	2.429	± 2.107
Arm 2: Unresectable (Proton Beam Therapy)	1.714	± 2.603

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1	± 0.632
Arm 2: Unresectable (Proton Beam Therapy)	0.738	± 1.044

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the EuroQol (EQ-5D) Questionnaire Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The EQ-5D is a standardized 2-part, patient-administered instrument used for direct and indirect assessment of health state utilities. The first part asks respondents to "check the ONE box \[next to the appropriate statement\] that best describes your health TODAY" for each of 5 health dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The second part of the EQ-5D is a visual analogue scale (VAS) valuing current health state. Both the 5-item index score and the VAS score are transformed into a utility score between 0 "Worst health state" and 1

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.664	± 0.405
Arm 2: Unresectable (Proton Beam Therapy)	0.486	± 0.496

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.56	± 0.358
Arm 2: Unresectable (Proton Beam Therapy)	0.607	± 0.39

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.803	± 0.295
Arm 2: Unresectable (Proton Beam Therapy)	0.818	± 0.124

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.802	± 0.287
Arm 2: Unresectable (Proton Beam Therapy)	0.645	± 0.488

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.816	± 0.202
Arm 2: Unresectable (Proton Beam Therapy)	0.942	± 0.083

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the Medical Outcomes Study (MOS) Social Support Survey Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The 19-item MOS Social Support Survey was designed for use with patients with chronic diseases and measures how often different kinds of support are available, if needed. Response choices range from "none of the time" (1) to "all of the time" (5). A mean social support score for all 19 items is computed to a 0-100 scale with higher scores indicating a greater availability of social support.

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	89	± 14.2
Arm 2: Unresectable (Proton Beam Therapy)	71.1	± 25.8

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.2	± 15.8
Arm 2: Unresectable (Proton Beam Therapy)	83.4	± 24.4

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	90.2	± 15.9
Arm 2: Unresectable (Proton Beam Therapy)	98.4	± 3.3

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.5	± 25.3
Arm 2: Unresectable (Proton Beam Therapy)	84.2	± 27.3

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.2	± 16.8
Arm 2: Unresectable (Proton Beam Therapy)	98.7	± 1.9

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the 4-Item Center for Epidemiological Studies Depression Scale (CES-D) Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The CES-D questionnaire is a 20-item measure which evaluates depressive symptoms. This trial will make use of the validated 4-item screening version in order to reduce participant burden. Possible range of scores is 0-60, with the higher scores indicating the presence of more symptomatology.

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	19.763	± 13.438
Arm 2: Unresectable (Proton Beam Therapy)	16.355	± 11.098

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	16.67	± 7.287
Arm 2: Unresectable (Proton Beam Therapy)	15.914	± 11.118

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.47	± 4.758
Arm 2: Unresectable (Proton Beam Therapy)	14.15	± 8.316

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.47	± 5.845
Arm 2: Unresectable (Proton Beam Therapy)	14.15	± 10.184

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	11.21	± 5.368
Arm 2: Unresectable (Proton Beam Therapy)	11.21	± 4.158

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1.994	± 1.641
Arm 2: Unresectable (Proton Beam Therapy)	1.127	± 0.634

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	4.135	± 1.795
Arm 2: Unresectable (Proton Beam Therapy)	3.024	± 2.454

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1.012	± 1
Arm 2: Unresectable (Proton Beam Therapy)	1.31	± 1.112

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	2.429	± 2.107
Arm 2: Unresectable (Proton Beam Therapy)	1.714	± 2.603

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1	± 0.632
Arm 2: Unresectable (Proton Beam Therapy)	0.738	± 1.044

9 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.878	± 0.858
Arm 2: Unresectable (Proton Beam Therapy)	2.476

12 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	1.224	± 1.319
Arm 2: Unresectable (Proton Beam Therapy)	0.524	± 0.202

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.664	± 0.405
Arm 2: Unresectable (Proton Beam Therapy)	0.486	± 0.496

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.56	± 0.358
Arm 2: Unresectable (Proton Beam Therapy)	0.607	± 0.39

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.803	± 0.295
Arm 2: Unresectable (Proton Beam Therapy)	0.818	± 0.124

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.802	± 0.287
Arm 2: Unresectable (Proton Beam Therapy)	0.645	± 0.488

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.816	± 0.202
Arm 2: Unresectable (Proton Beam Therapy)	0.942	± 0.083

9 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.863	± 0.161
Arm 2: Unresectable (Proton Beam Therapy)	0.734	± 0.377

12 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	0.84	± 0.181
Arm 2: Unresectable (Proton Beam Therapy)	1	± 0

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	89.0	± 14.2
Arm 2: Unresectable (Proton Beam Therapy)	71.1	± 25.8

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.2	± 15.8
Arm 2: Unresectable (Proton Beam Therapy)	83.4	± 24.4

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	90.2	± 15.9
Arm 2: Unresectable (Proton Beam Therapy)	98.4	± 3.3

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.5	± 25.3
Arm 2: Unresectable (Proton Beam Therapy)	84.2	± 27.3

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	88.2	± 16.8
Arm 2: Unresectable (Proton Beam Therapy)	98.7	± 1.9

9 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	87.5	± 18.8
Arm 2: Unresectable (Proton Beam Therapy)	99.3	± 0.9

12 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	91.8	± 11.3
Arm 2: Unresectable (Proton Beam Therapy)	100	± 0

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	19.763	± 13.438
Arm 2: Unresectable (Proton Beam Therapy)	16.355	± 11.098

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	16.67	± 7.287
Arm 2: Unresectable (Proton Beam Therapy)	15.914	± 11.118

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.47	± 4.758
Arm 2: Unresectable (Proton Beam Therapy)	14.15	± 8.316

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.47	± 5.845
Arm 2: Unresectable (Proton Beam Therapy)	14.15	± 10.184

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	11.21	± 5.368
Arm 2: Unresectable (Proton Beam Therapy)	11.21	± 4.158

9 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.89	± 5.052
Arm 2: Unresectable (Proton Beam Therapy)	8.27	± 0

12 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	12.843	± 5.323
Arm 2: Unresectable (Proton Beam Therapy)	8.27	± 0

Physician-reported Toxicity of PBT for Esophageal Cancer Primary · Through 6 months following chemoradiation (estimated to be 9 months)

Number of participants with grade 3 or higher specific cardiac, metabolism/nutrition, gastrointestinal, respiratory/thoracic/mediastinal, and skin/subcutaneous toxicity using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 related to PBT

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	2
Arm 2: Unresectable (Proton Beam Therapy)	0

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the SF-12 Questionnaire - Mental Component Score Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The SF-12 will be measured at each of 7 interviews, and mental and physical component scores will be calculated in addition to calculating the measure's eight individual subscales (physical functioning, social functioning, role limitations due to physical problems, body pain, general health, role limitations due to emotional problems general health, vitality, and mental health). Higher scores indicate better quality of life. MCS scores from the SF-12 are recoded, weighted, and summed, and standardized by the SF-12 scoring procedure. SF-12 is a licensed product and this procedure is implemente

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	45.0	± 15.1
Arm 2: Unresectable (Proton Beam Therapy)	44.5	± 16.4

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	45.7	± 9.6
Arm 2: Unresectable (Proton Beam Therapy)	45.7	± 13.0

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	50.9	± 11.0
Arm 2: Unresectable (Proton Beam Therapy)	45.3	± 15.9

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	50.4	± 10.2
Arm 2: Unresectable (Proton Beam Therapy)	44.6	± 12.3

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	50.8	± 8.2
Arm 2: Unresectable (Proton Beam Therapy)	54.7	± 1.4

Change in Patient-reported Outcomes of PBT for Esophageal Cancer as Measured by the SF-12 Questionnaire - Physical Component Score Primary · Baseline, post completion of chemoradiation, 2 months, 4 months, and 6 months

The SF-12 will be measured at each of 7 interviews, and mental and physical component scores will be calculated in addition to calculating the measure's eight individual subscales (physical functioning, social functioning, role limitations due to physical problems, body pain, general health, role limitations due to emotional problems general health, vitality, and mental health). Higher scores indicate better quality of life. PCS scores from the SF-12 are recoded, weighted, and summed, and standardized by the SF-12 scoring procedure. SF-12 is a licensed product and this procedure is implemente

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	45.8	± 12.6
Arm 2: Unresectable (Proton Beam Therapy)	41.9	± 18.1

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	33.5	± 10.5
Arm 2: Unresectable (Proton Beam Therapy)	37.6	± 11.4

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	40.4	± 12.0
Arm 2: Unresectable (Proton Beam Therapy)	39.4	± 12.6

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	42.6	± 13.3
Arm 2: Unresectable (Proton Beam Therapy)	42.9	± 14.2

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	42.3	± 12.0
Arm 2: Unresectable (Proton Beam Therapy)	51.9	± 6.1

The SF-12 will be measured at each of 7 interviews, and mental and physical component scores will be calculated in addition to calculating the measure's eight individual subscales (physical functioning, social functioning, role limitations due to physical problems, body pain, general health, role limitations due to emotional problems general health, vitality, and mental health). Higher scores indicate better quality of life. PCS scores from the SF-12 are recoded, weighted, and summed, and standardized by the SF-12 scoring procedure. SF-12 is a licensed product and this procedure is implemente

Baseline

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	45.8	± 12.6
Arm 2: Unresectable (Proton Beam Therapy)	41.9	± 18.1

Post completion of chemoradiation

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	33.5	± 10.5
Arm 2: Unresectable (Proton Beam Therapy)	37.6	± 11.4

2 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	40.4	± 12.0
Arm 2: Unresectable (Proton Beam Therapy)	39.4	± 12.6

4 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	42.6	± 13.3
Arm 2: Unresectable (Proton Beam Therapy)	42.9	± 14.2

6 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	42.3	± 12.0
Arm 2: Unresectable (Proton Beam Therapy)	51.9	± 6.1

9 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	43.9	± 9.8
Arm 2: Unresectable (Proton Beam Therapy)	40.4	± 17.6

12 months

Group	Value	95% CI
Arm 1: Resectable (Proton Beam Therapy)	42.1	± 11.1
Arm 2: Unresectable (Proton Beam Therapy)	39.8	± 7.2

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events are collected from start of treatment through 1 year. All-cause mortality is collected from start of treatment through 5 years.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm 1: Resectable (Proton Beam Therapy)

Serious: 12/15 (80%)

Deaths: 8/15

Arm 2: Unresectable (Proton Beam Therapy)

Serious: 4/6 (67%)

Deaths: 4/6

Serious adverse events (31 terms)

Reaction	System	Arm 1: Resectable (Proton …	Arm 2: Unresectable (Proto…
Disease progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Dysphagia	Gastrointestinal disorders	—	—
Sepsis	Infections and infestations	—	—
Dehydration	Metabolism and nutrition disorders	—	—
Generalized muscle weakness	Musculoskeletal and connective tissue disorders	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—
Atrioventricular block first degree	Cardiac disorders	—	—
Chest pain-cardiac	Cardiac disorders	—	—
Heart failure	Cardiac disorders	—	—
Pericardial effusion	Cardiac disorders	—	—
Pericardial tamponade	Cardiac disorders	—	—
Abdominal distension	Gastrointestinal disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Ascites	Gastrointestinal disorders	—	—
Enterocolitis	Gastrointestinal disorders	—	—
Esophagitis	Gastrointestinal disorders	—	—
Gastric ulcer	Gastrointestinal disorders	—	—
Hemorrhoidal hemorrhage	Gastrointestinal disorders	—	—
Abdominal infection	Infections and infestations	—	—
COVID-19 infection	Infections and infestations	—	—
Anorexia	Metabolism and nutrition disorders	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
ACE induced cough	Respiratory, thoracic and mediastinal disorders	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—

Other adverse events (7 terms — click to expand)

Reaction	System	Arm 1: Resectable (Proton …	Arm 2: Unresectable (Proto…
Diarrhea	Gastrointestinal disorders	—	—
Gastric stenosis	Gastrointestinal disorders	—	—
Hepatitis viral	Infections and infestations	—	—
Sepsis	Infections and infestations	—	—
Flank pain	Musculoskeletal and connective tissue disorders	—	—
Aspiration	Respiratory, thoracic and mediastinal disorders	—	—
Dyspnea	Respiratory, thoracic and mediastinal disorders	—	—

Most-reported serious reactions: Disease progression, Dysphagia, Sepsis, Dehydration, Generalized muscle weakness, Febrile neutropenia, Atrioventricular block first degree, Chest pain-cardiac.

Data from ClinicalTrials.gov NCT03482791 adverse events section.

Sponsor's own description

The investigators plan to include both operable and inoperable patients with esophagus cancer in this prospective trial. Since both proton and photon treatments are biologically equivalent, the investigators do not expect a difference in tumor control compared to intensity modulated radiation therapy (IMRT). The investigators have a prospective experience of physician-reported toxicity and patient outcome using IMRT for patients with inoperable esophagus cancer that will serve as a comparison group. For the resectable patients receiving trimodality therapy (chemoradiation followed by surgery), the investigators will carefully track toxicity and patient outcomes prospectively. The central hypothesis is that the biologic efficacy for tumor control should be similar between protons and photons, and therefore survival measures should be similar between the two groups, but that the main difference lies in the total severe toxicities experienced by the patients undergoing therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The modern approach to esophagectomy-review of the shift towards minimally invasive surgery.
Dolan DP, Swanson SJ. · · 2021 · cited 3× · PMID 34164535 · DOI 10.21037/atm.2020.03.143

Verify or expand the search:

Other trials of Proton beam therapy

Trials testing the same drug.

NCT05655078 — Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma · NA · recruiting
NCT01963429 — Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC · NA · completed

Other recruiting trials for Esophagus Cancer

Currently open trials in the same condition.

NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
NCT06550063 — HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes · recruiting
NCT06385717 — Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer · recruiting
NCT06430658 — Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer · Phase 2 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03482791 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03482791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03482791

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (31 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Proton beam therapy

Other recruiting trials for Esophagus Cancer

Other Washington University School of Medicine trials

Verify against primary sources